Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM)

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has formally submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Lucid-21-302 (Lucid-MS), its new drug candidate for the treatment of multiple sclerosis (MS). This milestone IND submission supports Quantum’s planned Phase 2 clinical trial evaluating its first-in-class therapeutic treatment targeting demyelination, advancing Quantum BioPharma’s strategic growth in the global neurological market.

Strategic Partnership with Global Clinical Research Organization (CRO) Signifies Advancement in Clinical Development of Lucid-21-302 (Lucid-MS), a Novel First-in-Class Treatment Inhibiting Demyelination

Financial Statements as of Date of Filing Show Strong Improvements in Cash, Reduction in Accounts Payable, and a Cash Runway Through January 2028

Highlights advancement of first-in-class neuroprotective candidate targeting demyelination

unbuzzd Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. (“Quantum” or the “Company”) (NASDAQ: QNTM).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. (“Quantum” or the “Company”) (NASDAQ: QNTM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. (“Quantum” or the “Company”) (NASDAQ: QNTM).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. (“Quantum” or the “Company”) (NASDAQ: QNTM).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. (“Quantum” or the “Company”) (NASDAQ: QNTM).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - January 12, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”)(NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - January 10, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - January 9, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - January 8, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - January 7, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - January 6, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - January 5, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.